The Inflation Reduction Act represents the biggest shake-up in pharmaceutical pricing in decades. Join PDG's Dan Snyder and industry expert Chuck Collins as they break down what the IRA means for pharma companies. From Medicare price negotiations to the new $2,000 out-of-pocket cap, discover how this legislation will transform drug pricing, market access, and competitive dynamics. Essential viewing for pharmaceutical executives and commercial leaders looking to navigate this new landscape.

Watch the full webinar here.

About Performance Development Group (PDG):

PDG is a specialty consulting firm dedicated to driving lasting performance improvements in life sciences’ client-facing teams. For over 20 years, we've helped commercial teams close execution gaps and adapt to industry changes through innovative coaching and behavioral change solutions.

Connect with us: Visit our website to learn how PDG can help your organization navigate industry changes and optimize commercial performance.

Follow us on LinkedIn.